Features of brachytherapy of secondary vaginal cancer with due regard for radiobiological aspects

The analysis of the direct outcomes of the effectiveness of the use of ⁶⁰Co or ¹⁹²Ir sources with HDR brachytherapy and dynamic observation data for 3 months showed that the positive tumor response (complete + partial regression) in patients with metastatic vaginal cancer after the course of chemoradiotherapy increased by 19.7 % and 14.5 % compared to ⁶⁰Co MDR in brachytherapy. Toxic effects of treatment concerned with the number and extent of their manifestations in the study groups of patients did not differ from the control group and did not exceed the second degree. The use of ¹⁹²Ir HDR and ⁶⁰Co HDR in combined radiotherapy in patients with secondary (metastatic) vaginal cancer makes it possible to enhance the therapeutic effect of radiotherapy, substantially improve the immediate outcomes of treatment of patients with secondary (metastatic) vaginal cancer without increasing toxicity (general and local), quantity and extent of possible early and late local radiation complications involving the key organs, which is due to the high accuracy of pre-irradiation preparation and adequate planning. The clinical effect of chemoradiotherapy is delayed. The use of radio modifiers in the process of combined radiotherapy in patients with metastatic vaginal cancer does not lead to toxic complications that adversely affect the quality of life of patients.